ClC-2 Inhibitors
2 drugsAbout ClC-2
ClC-2 is a chloride channel protein that regulates chloride ion flow across cell membranes, influencing cellular excitability, fluid transport, and pH regulation.
While there is currently no genetic evidence directly linking ClC-2 to specific diseases, its physiological roles have made it a target of interest for pharmaceutical intervention.
ClC-2 is targeted by two FDA-approved small molecule drugs: Lubiprostone (Amitiza) and Lubiprostone. These drugs are marketed by Zydus Pharms and Sucampo Pharma LLC.
Top ClC-2 Drugs
The competitive landscape consists of two companies: Zydus Pharms and Sucampo Pharma LLC.
Low market concentration suggests relatively low barriers to entry for new competitors.
ClC-2 Drug Modality Landscape
Modalities
Routes of Administration
ClC-2 is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies could provide a competitive advantage.
ClC-2 Clinical Trials 35 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on ClC-2. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 4 | 3 | 0 | 1 | 100% |
| Phase 2 | 5 | 3 | 1 | 1 | 75% |
| Phase 3 | 17 | 16 | 0 | 1 | 100% |
| Phase 4 | 9 | 8 | 1 | 0 | 89% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
ClC-2 Drug Approval Timeline (2006 - 2021)
The first drug was approved in 2006 (Amitiza), with the most recent in 2021 (Lubiprostone), spanning 16 years.
The approval timeline indicates continued interest in ClC-2 modulation, but potential saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 25 (6 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on ClC-2. A trial counts if an approved drug acting on ClC-2 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.